TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TILT-123’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TILT-123 is under development for the treatment of metastatic melanoma, ovarian cancer, peritoneal cancer, non-small cell lung cancer, lung cancer and fallopian tube cancer, SCCHN and refractory solid tumors. TILT-123 is a 5/3 chimeric serotype oncolytic adenovirus expressing human TNFalpha and human IL-2. TILT-123 is administered through intra-tumoral or intravenous route. The drug candidate is being developed as chimeric antigen receptor T cells for solid tumor.
TILT Biotherapeutics overview
TILT Biotherapeutics is a preclinical stage company that develops cancer immunotherapies. The company uses oncolytic viruses for enabling tumor T-cell therapy by tumor-infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy for solid tumor. Its pipeline products include TILT-123, TILT-234 and TILT-321. TILT Biotherapeutics’ TILT-123 is a lead candidate used for the treatment of melanoma and solid tumors. The company’s TILT-234 is used for dendritic cell therapy and solid tumors. It uses T-cell therapy to extract T-cells from the cancer patients. TILT Biotherapeutics is headquartered in Helsinki, Finland.
For a complete picture of TILT-123’s drug-specific PTSR and LoA scores, buy the report here.